1. “Current and Future Trends in Jobs for Veterinary Pathologists” Co-Chairs: Drs. Jon Werner (Amgen) and Kevin Lahmers (Washington St. Univ) Panelists: Drs. Chris Clarke (Amgen), John Cullen (NC St Univ), Kevin Keane (Consultant), Kevin Lahmers, Charles Wood (EPA), and Aaron Sargeant (CRL) 1

2.  Introduction (5 min)  Brief statements from panelists (20 min) ◦ Please hold questions  Open discussion (35 min) ◦ Before talking, please ID yourself  Continued discussion over cocktails 2

3. 3 Paraphrased opinion from Terry Leyden from the Leyden Group, a private recruiting firm in toxicology for over 30 years, and supporter of the ACVP/STP coalition:  Through 2008, there was a healthy job market for early career pathologists.  Since that time, this market has virtually disappeared due to: ◦ Large and mid sized pharma reducing staff and small biotech lacking funding. ◦ CROs having work volume drop, and sufficient staffing. ◦ Experienced pathologists leaving industry and offering consulting services.  However, there will be a large number of experienced pathologists retiring soon - "brain drain". Companies should consider succession planning.

4. NCSU Davis/Penn Hiring level  empty positions filled  No new positions created Qualifications  PhD generally required  High level of competition  Lots of good diagnosticians available Desirables  Research training/program  High level of competition Vet Schools contracting slightly due to state funding issues Some new positions available, but… Need to have the right niche  Specialized diagnostic skills  Research program  Tox path depends on regional support Hiring in Academia Dr. John Cullen, NC State

5.  In the past year, there has been a significant uptick in jobs posted  There are a lot of people looking  Do things to help yourself stand out ◦ Boards ◦ PhD ◦ Teaching experience ◦ Specialize-to an extent  It is currently largely about fit in the current buyer’s market

6.  Qualifications – DVM, DACVP, PhD….. ◦ DABT, MD  Experience – drug discovery and development ◦ Discovery science – peer engagement ◦ Tox Path – characterization, interpretation, risk assessment ◦ Drug development projects ◦ Technology-savvy, integrate data ◦ Pharma  CRO  academia ◦ Management/leadership  Behaviors ◦ Team player ◦ “Leadership” ◦ Problem solver, critical thinker ◦ Proactive ◦ Communication skills ◦ Inquisitive ◦ Adaptive

7.  Flexibility  Team player with broad skills and interests  How are these influences changing pathology? - genomics, paraprofessionals, automated slide reading, 3R’s, offshoring, …

8.  Widespread tightening of science/R&D budgets across federal agencies  Pressure on basic science and bench pathology roles  More emphasis on translational scientist and advisor roles  Traditional pathology skills important, bridge skills critical ◦ Examples: Toxicology, Molecular biology/Biomarkers, Computational biology/Informatics

9.  Pharma Tox. Pathology: In-depth Tox Path knowledge of a drug class or target  GLP Lab Animal Veterinarian: Team effort to have animals & facility for tox studies  Drug Program Leader: Team effort to move a novel compound to clinical trials  CRO Pathology: In-depth Tox Path knowledge of spontaneous vs. test article findings  International: Understanding how to work & teach in China & India  Society of Tox Path: Source of continuous learning and consortium building

10. 201220112010200920082007 Net Income Corp. A3525(380)37(596)104 Corp. B4105(32)100205196 200620052004200320022001 Net Income Corp. A826832183426 Corp. B154140112836748